These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 18410949)

  • 21. Herpes simplex virus-2 in the genital mucosa: insights into the mucosal host response and vaccine development.
    Lee AJ; Ashkar AA
    Curr Opin Infect Dis; 2012 Feb; 25(1):92-9. PubMed ID: 22143115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Susceptibility of CCR5-deficient mice to genital herpes simplex virus type 2 is linked to NK cell mobilization.
    Thapa M; Kuziel WA; Carr DJ
    J Virol; 2007 Apr; 81(8):3704-13. PubMed ID: 17267483
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Construction and properties of a herpes simplex virus 2 dl5-29 vaccine candidate strain encoding an HSV-1 virion host shutoff protein.
    Reszka NJ; Dudek T; Knipe DM
    Vaccine; 2010 Mar; 28(15):2754-62. PubMed ID: 20117270
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overexpression of interleukin-15 compromises CD4-dependent adaptive immune responses against herpes simplex virus 2.
    Gill N; Ashkar AA
    J Virol; 2009 Jan; 83(2):918-26. PubMed ID: 19004955
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protection from genital herpes disease, seroconversion and latent infection in a non-lethal murine genital infection model by immunization with an HSV-2 replication-defective mutant virus.
    Diaz FM; Knipe DM
    Virology; 2016 Jan; 488():61-7. PubMed ID: 26609935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Herpes simplex virus (HSV)-specific T cells activated in the absence of IFN-gamma express alternative effector functions but are not protective against genital HSV-2 infection.
    Johnson AJ; Nelson MH; Bird MD; Chu CF; Milligan GN
    J Reprod Immunol; 2010 Jan; 84(1):8-15. PubMed ID: 19942296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protective immunity to genital herpes simplex [correction of simpex] virus type 2 infection is mediated by T-bet.
    Svensson A; Nordström I; Sun JB; Eriksson K
    J Immunol; 2005 May; 174(10):6266-73. PubMed ID: 15879125
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Herpes Simplex Virus 2 (HSV-2) gD Mutant Impaired for Neural Tropism Is Superior to an HSV-2 gD Subunit Vaccine To Protect Animals from Challenge with HSV-2.
    Wang K; Goodman KN; Li DY; Raffeld M; Chavez M; Cohen JI
    J Virol; 2016 Jan; 90(1):562-74. PubMed ID: 26559846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs.
    Hoshino Y; Dalai SK; Wang K; Pesnicak L; Lau TY; Knipe DM; Cohen JI; Straus SE
    J Virol; 2005 Jan; 79(1):410-8. PubMed ID: 15596834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intramuscular delivery of replication-defective herpes simplex virus gives antigen expression in muscle syncytia and improved protection against pathogenic HSV-2 strains.
    Diaz F; Gregory S; Nakashima H; Viapiano MS; Knipe DM
    Virology; 2018 Jan; 513():129-135. PubMed ID: 29069622
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Maternal immunization with a herpes simplex virus type 2 replication-defective virus reduces visceral dissemination but not lethal encephalitis in newborn mice after oral challenge.
    Evans IA; Jones CA
    J Infect Dis; 2002 Jun; 185(11):1550-60. PubMed ID: 12023760
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A heat shock protein based polyvalent vaccine targeting HSV-2: CD4(+) and CD8(+) cellular immunity and protective efficacy.
    Mo A; Musselli C; Chen H; Pappas J; Leclair K; Liu A; Chicz RM; Truneh A; Monks S; Levey DL; Srivastava PK
    Vaccine; 2011 Nov; 29(47):8530-41. PubMed ID: 21767588
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigs.
    Bernard MC; Barban V; Pradezynski F; de Montfort A; Ryall R; Caillet C; Londono-Hayes P
    PLoS One; 2015; 10(4):e0121518. PubMed ID: 25837802
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of herpes simplex virus-specific T cells in the murine female genital tract following genital infection with herpes simplex virus type 2.
    Milligan GN; Bernstein DI
    Virology; 1995 Oct; 212(2):481-9. PubMed ID: 7571418
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunization with a replication-defective herpes simplex virus 2 mutant reduces herpes simplex virus 1 infection and prevents ocular disease.
    van Lint AL; Torres-Lopez E; Knipe DM
    Virology; 2007 Nov; 368(2):227-31. PubMed ID: 17915278
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response.
    Bettahi I; Zhang X; Afifi RE; BenMohamed L
    Viral Immunol; 2006; 19(2):220-36. PubMed ID: 16817765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of genital T cell responses to herpes simplex virus type 2 resulting from immunization of the nasal mucosa.
    Milligan GN; Dudley-McClain KL; Chu CF; Young CG
    Virology; 2004 Jan; 318(2):507-15. PubMed ID: 14972519
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccination with the Secreted Glycoprotein G of Herpes Simplex Virus 2 Induces Protective Immunity after Genital Infection.
    Önnheim K; Ekblad M; Görander S; Bergström T; Liljeqvist JÅ
    Viruses; 2016 Apr; 8(4):110. PubMed ID: 27110813
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of mucosal and parenteral immunization with a replication-defective mutant of HSV-2 on immune responses and protection from genital challenge.
    Morrison LA; Da Costa XJ; Knipe DM
    Virology; 1998 Mar; 243(1):178-87. PubMed ID: 9527927
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DNA immunization confers protective immunity on mice challenged intravaginally with herpes simplex virus type 2.
    Bourne N; Milligan GN; Schleiss MR; Bernstein DI; Stanberry LR
    Vaccine; 1996 Sep; 14(13):1230-4. PubMed ID: 8961510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.